Gastrointestinal Therapeutics Market Size
| Study Period | 2019-2029 |
| Market Size (2024) | USD 0.08 Billion |
| Market Size (2029) | USD 0.1 Billion |
| CAGR (2024 - 2029) | 3.80 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Gastrointestinal Therapeutics Market Analysis
The Gastrointestinal Therapeutics Market size is estimated at USD 0.08 billion in 2024, and is expected to reach USD 0.1 billion by 2029, growing at a CAGR of 3.80% during the forecast period (2024-2029).
Factors such as the increasing prevalence of gastrointestinal diseases and the rising investments in research and development by pharmaceutical companies are expected to boost the market growth.
The increasing burden of gastrointestinal diseases among the population raises the demand for effective drugs, which is expected to fuel market growth. For instance, as per the 2023 statistics published by the American Cancer Society, 2023, approximately 153,020 individuals were diagnosed with colorectal cancer (CRC) including 19,550 individuals younger than 50 years. Also, the 2023 update by Bower Cancer United Kingdom shows that bowel cancer is the fourth most common cancer, and approximately 47,700 people are diagnosed with bowel cancer every year in the United Kingdom. Additionally, as per an article published in NLM in July 2022, it was observed that GERD, the most prevalent gastrointestinal condition, affects 20% of individuals in Western culture. In addition, as per the same source, an estimated prevalence of GERD in the United States ranges between 18.1% and 27.8%, and the prevalence of GERD is higher among men than women. Thus, the high burden of GI tract diseases such as cancer and GERD is expected to increase demand for effective therapeutics approaches, thereby boosting the market growth.
Furthermore, the rising company's investment in research and development of gastro-related drugs and rising drug launches that increase the availability of the drugs in the market are also expected to fuel the market growth. For instance, in April 2022, Microbiotica received project funding from the Crohn's & Colitis Foundation, as part of their IBD Ventures program, for the development of therapies, Microbiotica's Live Bacterial Therapeutic (LBT) MB310 to treat ulcerative colitis or inflammatory bowel disease (IBD). The funding is utilized to advance MB310's development through cGMP production to support an investigational new drug (IND) application, which allows entry into a first-in-human clinical study.
Similarly, in November 2023, PanKind announced the recipients of over USD 1.8 million of grant funding to progress pancreatic cancer research in the key areas of Early Detection and New Treatments. Moreover, the rising company activities in developing novel drugs and increasing product launches are also contributing to the market growth. For instance, in April 2022, Ardelyx, Inc. launched IBSRELA, an NHE3 inhibitor for treating irritable bowel syndrome with constipation (IBS-C) in adults.
Therefore, owing to the factors above, such as the rising prevalence of GI disorders and the increasing R&D activities for the development of gastrointestinal disease treatment is likely to boost the growth of the gastrointestinal therapeutics market over the forecast period. However, stringent regulatory norms regarding drug approvals and an increasing number of patent expiries are expected to impede the market growth over the forecast period.
Gastrointestinal Therapeutics Market Trends
Ulcerative Colitis Segment is Expected to Witness Significant Growth Over the Forecast Period
Ulcerative colitis is a chronic inflammatory bowel disease (IBD) that causes inflammation and ulcers on the inner lining of the large intestine due to abnormal immune system reactions. Some drugs used to treat ulcerative colitis are Infliximab, Humira, Simponi, Entyvio, Stelara, Colazal, Dipentum, Azulfidine, and others. The expected growth in the ulcerative colitis segment can be attributed to various factors such as advances in research and development, along with the introduction of innovative treatments and therapies. Additionally, increased awareness, improved diagnostic techniques, and a rising prevalence of gastrointestinal disorders may drive the demand for effective therapies in this specific segment.
The growing burden of ulcerative colitis across the world is expected to create the demand for effective treatment, thereby boosting the segment growth. For instance, according to an article published in the National Library of Medicine in August 2023, Ulcerative colitis is a lifelong inflammatory disease affecting the rectum and colon to a variable extent. In 2023, the prevalence of ulcerative colitis was estimated to be 5 million cases around the world, and the incidence is increasing worldwide. Thus, the rising new and emerging treatments are expected to increase the availability of effective and safe drugs in the market, boosting segment growth.
Furthermore, the increasing drug approval and launches by regulatory bodies are expected to increase the availability of novel therapeutics for treating ulcerative colitis patients. It is anticipated to fuel the market growth over the forecast period. For instance, in December 2022, the United States FDA accepted Pfizer's New Drug Application (NDA) for etrasimod, an oral, once daily, selective sphingosine-1-phosphate (S1P) receptor modulator. It is designed for optimized pharmacology and S1P receptors 1, 4, and 5 engagements for individuals with moderately-to-severely active ulcerative colitis (UC).
Therefore, owing to the factors above, such as the growing burden of ulcerative colitis and product launches the studied segment is expected to grow over the forecast period.
North America is Expected to Hold a Significant Market Share Over the Forecast Period
North America is expected to hold a significant market share over the forecast period owing to factors such as the increasing burden of gastrointestinal diseases, rising product launches, and growing company initiatives.
The increasing burden of gastrointestinal diseases such as stomach cancer, colon cancer, GERD, ulcerative colitis, and others among the population is the key factor driving the market growth. For instance, as per an article published in NLM in July 2022, GERD was one of the most widespread gastrointestinal conditions, affecting 20% of adults in Western countries such as the United States. In addition, the estimated prevalence of GERD in the United States population ranges from 18.1% to 27.8%. Additionally, according to the Canadian Cancer Society (CCS) data reviewed in May 2022, colorectal cancer was expected to be Canada's fourth most commonly diagnosed cancer in 2022. Also, nearly 24,300 Canadians were diagnosed with colorectal cancer, representing 10% of all new cancer cases in Canada in 2022.
Furthermore, the rising government funding for gastrointestinal diseases research and development is expected to increase the company's focus on developing novel treatment drugs, propelling market growth. For instance, according to the data published by NIH, in May 2022, the government funded an estimated USD 352 million for the research and development of colorectal cancer disease in the United States in 2022, compared to USD 335 million in 2021. In addition, as per the same source, an estimated USD 92 million was funded by the government for research and development of Crohn's disease in 2022 as compared to USD 88 million in 2021.
Moreover, the rising drug launches and approvals in the region and an increasing company focus on adopting key strategies such as collaboration, partnerships, and others are also contributing to the market growth. For instance, in March 2022, AbbVie Inc. received United States FDA approval for its RINVOQ (upadacitinib) prescription medicine for treating adults' severe to moderate ulcerative colitis. Also, in October 2022, Phathom Pharmaceuticals signed a deal with Evonik to manufacture its recently FDA-approved gastrointestinal drug, vonoprazan. Similarly, in May 2021, BMS received United States FDA approval for Zeposia, a sphingosine 1-phosphate (S1P) receptor modulator, to treat moderate to severe ulcerative colitis.
Therefore, owing to the factors above, the studied segment is expected to grow over the forecast period.
Gastrointestinal Therapeutics Industry Overview
The gastrointestinal therapeutics market is moderately competitive with the presence of many market players. The companies are adopting key strategies such as new product development, collaborations, partnerships, and others to retain their market position. Some market players include Abbott Laboratories, Abbvie Inc., Cipla Inc., Bayer AG, GlaxoSmithKline PLC, Johnson & Johnson (Janssen Pharmaceuticals Inc.), Abbvie Inc, and Takeda Pharmaceutical Company Limited.
Gastrointestinal Therapeutics Market Leaders
Abbvie Inc.
Bayer AG
Cipla Inc
Abbott
Takeda Pharmaceutical Company Limited
*Disclaimer: Major Players sorted in no particular order
Gastrointestinal Therapeutics Market News
- October 2023: Sanofi and Teva Pharmaceuticals announced a collaboration to co-develop and co-commercialize asset TEV’574, currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn's Disease, two types of inflammatory bowel disease.
- April 2023: Seres Therapeutics, Inc. and Nestlé Health Science announced the United States Food and Drug Administration (FDA) approval of VOWSTTM (fecal microbiota spores, live-brpk), formerly called SER-109, an orally administered microbiota-based therapeutic to prevent recurrence of C. difficile Infection (CDI) in adults following antibacterial treatment for recurrent CDI (rCDI).
Gastrointestinal Therapeutics Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Gastrointestinal Diseases
4.2.2 Rising Investments in Research and Development by Pharmaceutical Companies
4.3 Market Restraints
4.3.1 Stringent Regulatory Norms Regarding Drug Approvals
4.3.2 Increasing Number of Patent Expiries
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Drug Type
5.1.1 Antacids
5.1.2 Laxatives
5.1.3 Antidiarrheal agents
5.1.4 Antiemetics
5.1.5 Antiulcer agents
5.1.6 Other Drug Types
5.2 By Dosage Form
5.2.1 Oral
5.2.2 Parenteral
5.2.3 Other Dosage Forms
5.3 By Application
5.3.1 Ulcerative Colitis
5.3.2 Irritable Bowel Syndrome
5.3.3 Crohn's Disease
5.3.4 Celiac Disease
5.3.5 Gastroenteritis
5.3.6 Other Applications
5.4 By Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPANY PROFILES AND COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Abbvie Inc.
6.1.3 AstraZeneca
6.1.4 Bayer AG
6.1.5 GlaxoSmithKline PLC
6.1.6 Janssen Global Services LLC (Johnson & Johnson)
6.1.7 Pfizer Inc.
6.1.8 Takeda Pharmaceutical Company Limited
6.1.9 Bausch Health Companies Inc. (Salix Pharmaceuticals Inc.)
6.1.10 Boehringer Ingelheim International GmbH
6.1.11 Cipla Inc.
6.1.12 Sebela Pharmaceuticals
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Gastrointestinal Therapeutics Industry Segmentation
As per the scope of the report, gastrointestinal disorders are medical conditions related to the digestive system that affect the colon, small and large intestine, and rectum. The disorders mainly include constipation, peptic ulcer diseases, and irritable bowel syndrome, characterized by various symptoms such as pain, bloating, diarrhea, nausea, and vomiting. The Gastrointestinal Therapeutics Market is Segmented By Drug Type (Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents, And Other Drug Types), Dosage Form (Oral, Parenteral, And Other Dosage Forms), Application (Ulcerative Colitis, Irritable Bowel Syndrome, Crohn's Disease, Celiac Disease, Gastroenteritis, And Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for the above segments.
| By Drug Type | |
| Antacids | |
| Laxatives | |
| Antidiarrheal agents | |
| Antiemetics | |
| Antiulcer agents | |
| Other Drug Types |
| By Dosage Form | |
| Oral | |
| Parenteral | |
| Other Dosage Forms |
| By Application | |
| Ulcerative Colitis | |
| Irritable Bowel Syndrome | |
| Crohn's Disease | |
| Celiac Disease | |
| Gastroenteritis | |
| Other Applications |
| By Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Gastrointestinal Therapeutics Market Research FAQs
How big is the Gastrointestinal Therapeutics Market?
The Gastrointestinal Therapeutics Market size is expected to reach USD 0.08 billion in 2024 and grow at a CAGR of 3.80% to reach USD 0.1 billion by 2029.
What is the current Gastrointestinal Therapeutics Market size?
In 2024, the Gastrointestinal Therapeutics Market size is expected to reach USD 0.08 billion.
Who are the key players in Gastrointestinal Therapeutics Market?
Abbvie Inc., Bayer AG, Cipla Inc, Abbott and Takeda Pharmaceutical Company Limited are the major companies operating in the Gastrointestinal Therapeutics Market.
Which is the fastest growing region in Gastrointestinal Therapeutics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Gastrointestinal Therapeutics Market?
In 2024, the North America accounts for the largest market share in Gastrointestinal Therapeutics Market.
What years does this Gastrointestinal Therapeutics Market cover, and what was the market size in 2023?
In 2023, the Gastrointestinal Therapeutics Market size was estimated at USD 0.08 billion. The report covers the Gastrointestinal Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Gastrointestinal Therapeutics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Global Gastrointestinal Therapeutics Industry Report
Statistics for the 2024 Gastrointestinal Therapeutics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Gastrointestinal Therapeutics analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
